Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Axsome Therapeutics (AXSM)

Axsome Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AXSM
DateTimeSourceHeadlineSymbolCompany
08/05/202412:00GlobeNewswire Inc.Axsome Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202422:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AXSMAxsome Therapeutics Inc
06/05/202413:09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
06/05/202412:00GlobeNewswire Inc.Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
01/05/202412:00GlobeNewswire Inc.Axsome Therapeutics Recognizes May as Mental Health Awareness MonthNASDAQ:AXSMAxsome Therapeutics Inc
15/04/202412:00GlobeNewswire Inc.Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:AXSMAxsome Therapeutics Inc
10/04/202412:00GlobeNewswire Inc.Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6NASDAQ:AXSMAxsome Therapeutics Inc
01/04/202412:00GlobeNewswire Inc.Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating DisorderNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202411:00GlobeNewswire Inc.Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 PatientsNASDAQ:AXSMAxsome Therapeutics Inc
25/03/202410:30GlobeNewswire Inc.Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in NarcolepsyNASDAQ:AXSMAxsome Therapeutics Inc
19/03/202411:00GlobeNewswire Inc.Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive DisorderNASDAQ:AXSMAxsome Therapeutics Inc
05/03/202412:00GlobeNewswire Inc.Axsome Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
29/02/202423:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
29/02/202423:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
29/02/202422:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AXSMAxsome Therapeutics Inc
27/02/202412:00GlobeNewswire Inc.Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:AXSMAxsome Therapeutics Inc
23/02/202413:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AXSMAxsome Therapeutics Inc
20/02/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
20/02/202412:00GlobeNewswire Inc.Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AXSMAxsome Therapeutics Inc
20/02/202410:37IH Market NewsMarket Cautiousness Ahead of Retail Giants’ Earnings; Oil Prices DipNASDAQ:AXSMAxsome Therapeutics Inc
14/02/202420:46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AXSMAxsome Therapeutics Inc
23/01/202412:00GlobeNewswire Inc.Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20NASDAQ:AXSMAxsome Therapeutics Inc
08/01/202412:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
04/01/202412:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
04/01/202412:00GlobeNewswire Inc.Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated MilestonesNASDAQ:AXSMAxsome Therapeutics Inc
11/12/202312:00GlobeNewswire Inc.Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual MeetingNASDAQ:AXSMAxsome Therapeutics Inc
07/12/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AXSMAxsome Therapeutics Inc
07/12/202312:00GlobeNewswire Inc.Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders TodayNASDAQ:AXSMAxsome Therapeutics Inc
22/11/202312:00GlobeNewswire Inc.Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7NASDAQ:AXSMAxsome Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AXSM